Financial Statement January 1 to December 31 2021
Faron Pharmaceuticals Ltd. (“Faron” or “Company”) Faron Financial Statement Release January 1 to December 31, 2021 Financial statement release March 25, 2022 at 09:00 AM (EET) / 07:00 AM (GMT) / 03:00 AM (EDT) Inside information 2021 Highlights · Bexmarilimab shows compelling antitumor activity in multiple advanced treatment resistant solid tumor types as a monotherapy with strongest clinical benefit rate (partial response or stable disease) observed in five different tumor types – cutaneous melanoma (30%), gastric cancer (30%), cholangiocarcinoma (30%),